NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The ...

Nevro Corp (NYSE:NVRO), a medical device company specializing in spinal cord stimulation (SCS) technology for chronic pain treatment, has recently undergone significant changes in its market position ...

Nevro Corp. (NYSE:NVRO – Get Free Report) has earned a consensus rating of “Reduce” from the thirteen research firms that are ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions ...

Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful ...

Patents covering Senza HFX iQ and other Nevro products are listed at Nevro/patents . To learn more about Nevro, visit and connect with us on LinkedIn , X , Facebook , and Instagram . Forward ...

Nevro has also focused on advancing its product portfolio. The launch of the HFX AdaptivAI platform in the U.S. in November 2024 represents a significant step in this direction. Additionally ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Nevro Corp. (NVRO) on Tuesday reported a loss of $53.1 million in its fourth quarter. On a per-share basis, the Redwood City ...